Adaptimmune Therapeutics plc

OTCPK:ADAP.Y Stock Report

Market Cap: US$10.9m

Adaptimmune Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:ADAP.Y Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Aug 25SellUS$348William Charles BertrandIndividual34,500US$0.01
18 Aug 25SellUS$38,195New Enterprise Associates, Inc.Company3,250,000US$0.012
30 Jul 25SellUS$1,148,373EcoR1 Capital, LLCCompany10,675,423US$0.11
17 Jan 25SellUS$17,773Adrian G. RawcliffeIndividual30,601US$0.58
17 Jan 25SellUS$3,243John LungerIndividual5,584US$0.58
17 Jan 25SellUS$3,243William Charles BertrandIndividual5,584US$0.58
17 Jan 25SellUS$3,243Elliot NorryIndividual5,584US$0.58
15 Jan 25SellUS$11,360William Charles BertrandIndividual19,542US$0.59
15 Jan 25SellUS$12,920Elliot NorryIndividual22,195US$0.59
15 Jan 25SellUS$11,360John LungerIndividual19,542US$0.59
15 Jan 25SellUS$7,467Cintia PiccinaIndividual12,991US$0.57
15 Jan 25SellUS$34,639Adrian G. RawcliffeIndividual59,569US$0.59

Insider Trading Volume

Insider Buying: ADAP.Y insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ADAP.Y?
Owner TypeNumber of SharesOwnership Percentage
State or Government73,3760.0277%
Individual Insiders1,713,4780.646%
VC/PE Firms13,829,7785.22%
Institutions36,590,66813.8%
Hedge Funds46,337,38817.5%
General Public166,559,91362.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 36.67% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.96%
Long Focus Capital Management LLC
23,756,687US$973.8k0%0.07%
8.52%
Two Seas Capital LP
22,580,701US$925.6k9.99%0.06%
5.22%
New Enterprise Associates, Inc.
13,829,778US$566.9k-19%0.04%
4.15%
EcoR1 Capital, LLC
11,000,000US$450.9k-59.9%0.02%
3.48%
MPM BioImpact LLC
9,221,498US$378.0k-9.86%0.05%
1.6%
Morgan Stanley
4,231,983US$173.5k55.8%no data
0.94%
Rock Springs Capital Management LP
2,483,468US$101.8k0%0.01%
0.74%
Acadian Asset Management LLC
1,964,141US$80.5k-11.4%no data
0.71%
Renaissance Technologies LLC
1,882,860US$77.2k3.8%no data
0.43%
Bank of America Corporation
1,141,713US$46.8k-0.46%no data
0.3%
Empirical Finance, LLC
800,000US$32.8k0%no data
0.26%
Garry Menzel
686,295US$28.1k0%no data
0.2%
Mercer Investments LLC
538,309US$22.1k0%no data
0.19%
B. Riley Wealth Advisors, Inc.
500,000US$20.5k0%no data
0.16%
Rathbones Investment Management Limited
432,818US$17.7k0%no data
0.16%
State Street Global Advisors, Inc.
426,714US$17.5k1.29%no data
0.15%
Adrian G. Rawcliffe
395,227US$16.2k0%no data
0.13%
Impresa Management LLC
340,409US$14.0k-78.4%no data
0.068%
BlackRock, Inc.
179,087US$7.3k-2.5%no data
0.064%
John Lunger
170,890US$7.0k0%no data
0.062%
William Charles Bertrand
164,392US$6.7k-17.4%no data
0.05%
Elliot Norry
133,265US$5.5k0%no data
0.047%
FMR LLC
123,869US$5.1k-29.7%no data
0.042%
Cintia Piccina
111,073US$4.6k503%no data
0.042%
Lakeridge Wealth Management LLC
110,400US$4.5k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/05 22:51
End of Day Share Price 2025/11/05 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adaptimmune Therapeutics plc is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Ying HuangBofA Global Research
Mohit BansalCitigroup Inc